Published in

Esmo Open, Esmo Open, 2(6), p. 100078, 2021

DOI: 10.1016/j.esmoop.2021.100078

Links

Tools

Export citation

Search in Google Scholar

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

Journal article published in 2021 by G. L. Banna, A. Cortellini, D. L. Cortinovis, M. Tiseo, J. G. J. V. Aerts, F. Barbieri, R. Giusti, E. Bria, F. Grossi, P. Pizzutilo, R. Berardi, A. Morabito, C. Genova, F. Mazzoni, V. Di Noia and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Question mark in circle
Preprint: policy unknown
Upload
Question mark in circle
Postprint: policy unknown
Upload
Question mark in circle
Published version: policy unknown
Upload
Policy details
Data provided by SHERPA/RoMEO